Skip to Content
Hae Menu

Promising results for adjuvant pembrolizumab therapy in high-risk kidney cancer

Results from KEYNOTE-564 presented after the plenary session of ASCO 2021 show that adjuvant pembrolizumab therapy leads to a significant reduction in the risk of recurrence or death compared to placebo in patients with renal cell carcinoma.

Human Kidney Cross Section

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Asiaan liittyvä sisältö

Azacitidine was generally well tolerated in patients ≥ 75 years of age in QUAZAR AML-001

/ BestPractice Nordic
EHA21AML

CAR-T cell therapy provides early and deep response in multiple myeloma patients

/ BestPractice Nordic
myeloomaEHA21

mutNPM1 status is a prognostic and an independent predictive marker for improved survival with azacitidine

/ BestPractice Nordic
EHA21AML
Back to top